A Phase 2 interventional study of LOU064 100 mg and Placebo in Asthma, sponsored by Novartis Pharmaceuticals. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-10-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Asthma by Novartis — 3 open to participants now, 5 under way, 2 of them phase 3. Asthma · Novartis.
Among the 105 studies in Asthma by Novartis, this one is the 56th largest by enrollment of the 97 interventional ones that give a count, is one of 4 that started in 2019, is one of 43 in phase 2, and was the 92nd registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →3 of the 105 studies in Asthma by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Argentina, France, Germany and 7 more countries
Ages 12–17
Novartis Pharmaceuticals · Sites in Argentina, Austria, Brazil and 14 more countries
Ages 6–11
Novartis Pharmaceuticals · Sites in Bulgaria, Colombia, Guatemala and 5 more countries
Ages 6–11
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 49 · Phase 3 33 · Phase 4 13
First in 2001; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is close to the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 98 across the 97 interventional studies, 454 across the 8 observational. Of the 93 that completed or were terminated, 61 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Asthma by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05274425Novartis PharmaceuticalsA 24-week rPMS Study in Real-world Setting for Enerzair | 2026-12-23 |
| NCT05217810Novartis PharmaceuticalsA 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® | 2026-12-24 |
| NCT05222529Novartis PharmaceuticalsPharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 105 studies in Asthma by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a proof-of-concept study to evaluate the efficacy of LOU064 in patients with inadequately controlled asthma. All subjects were randomized with 3:2 ratio to receive LOU064 100 mg once daily or LOU064 matching placebo for 12 weeks with standard background therapy of budesonide 80 µg/formoterol 4.5 µg two inhalations twice a day (b.i.d).
This was a non-confirmatory, multi-center, randomized, placebo-controlled, subject- and investigator-blinded, parallel-group study to evaluate the efficacy and safety of LOU064 in patients with inadequately controlled asthma who were on a standardized background therapy of inhaled corticosteroid plus long acting beta-2 agonist (ICS/LABA).
The study included:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have been treated with:
Exclusion Criteria:
History or current diagnosis of abnormalities indicating significant risk of safety for subjects participating in the study such as:
Hematology parameters at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LOU064 100 mg once daily orally
Drug: LOU064 100 mg
Placebo once daily orally
Drug: Placebo
LOU064 100 mg once daily orally administered as two 50 mg capsules
Placebo once daily administered orally as capsules
Change From Baseline in Pre-dose FEV1 at Week 12
FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre-dose. The baseline pre-dose FEV1 is defined as the average of the FEV1 measurements performed 45 min and 15 min prior to dosing on Day 1. A positive change from baseline in pre-dose FEV1 is considered a favorable outcome. Change from baseline in pre-dose FEV1 was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*visit interaction and baseline pre-dose FEV1. A weakly informative prior was considered for the placebo response.
Time frame: Baseline, Week 12
Maximum Observed Blood Concentrations (Cmax) of LOU064 at Steady State
Pharmacokinetic (PK) parameters were calculated based on LOU064 blood concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1 ng/mL. Cmax was determined using non-compartmental methods.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85
Time to Reach Maximum Blood Concentrations (Tmax) of LOU064 at Steady State
PK parameters were calculated based on LOU064 blood concentrations determined by a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. Tmax was determined using non-compartmental methods.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85
Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24h) of LOU064 at Steady State
PK parameters were calculated based on LOU064 blood concentrations determined by a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. AUC0-24h was determined using non-compartmental methods. The linear trapezoidal rule was used for AUC0-24h calculation.
Time frame: pre-dose, 0.5, 1, 2, 3 and 4 hours after dosing on Days 15 and 85
Change From Baseline in Asthma Symptom Questionnaire-5 Score (ACQ-5) at Week 12
The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the overall ACQ-5 score is the mean of all 5 questions, therefore between 0 (totally controlled) and 6 (severely uncontrolled). The baseline values of ACQ-5 were collected at the baseline visit. A negative change from baseline in ACQ-5 is considered a favorable outcome. Change from baseline in ACQ-5 score was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*visit interaction and baseline ACQ-5 score. Non-informative priors were considered.
Time frame: Baseline, Week 12
Change From Baseline in Mean Morning and Mean Evening Peak Expiratory Flow (PEF)
PEF (Peak Expiratory Flow) is a person's maximum speed of expiration. All participants were instructed to record PEF twice daily before taking any medication using an electronic peak expiratory flow device (ePEF), once in the morning and once approximately 12 h later in the evening at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. For each day the best value in the morning and in the evening were considered and mean values on 4-week intervals were derived. The baseline values of PEF were the mean values in the run-in period. A positive change from baseline in PEF is considered a favorable outcome. Change from baseline in mean morning and mean evening PEF were analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*weeks interaction and baseline PEF values. Non-informative priors were considered.
Time frame: Baseline, Weeks 9-12
Change From Baseline in Number of Puffs of SABA Taken Per Day During the Treatment Period
Participants were given a short acting β2-agonist (SABA; salbutamol, known also as albuterol) to use as rescue medication throughout the study along with an electronic diary (eDiary) to record rescue medication use. Participants recorded in the eDiary, once in the morning and once in the evening, the use of rescue medication (number of puffs of SABA taken in the previous 12 hours). The total number of puffs of SABA taken per day was calculated and the mean daily use of puffs of SABA over 12 weeks was derived. The baseline values of number of puffs of SABA taken per day were defined as the average from all non-missing records taken during the run-in period. A negative change from baseline is considered a favorable outcome. Change from baseline in number of puffs of SABA taken per day was analyzed using a Bayesian model, adjusting for effects of baseline SABA use, baseline FEV1, baseline asthma daytime symptom score and treatment. Non-informative priors were considered.
Time frame: Baseline, 12 weeks
Change From Baseline in Daytime and Nighttime Asthma Symptom Score
Participants recorded asthma symptoms twice daily in the eDiary. Daytime asthma symptoms were assessed before bed and nighttime symptoms on awakening. * Daytime asthma symptom score included 4 questions. Overall score (0 to 6) was calculated as the average of the 4 questions with higher values indicating more asthma symptoms. * Nighttime asthma symptom score included 2 questions. Overall score (0 to 3.5) was calculated as the average of the 2 questions with higher values indicating more asthma symptoms. Mean values of both scores were calculated over 4-week intervals during the treatment period. The baseline values of both asthma symptoms scores were defined as the average score during the run-in period. A negative change from baseline is a favorable outcome. Change from baseline in daytime and nighttime asthma symptom score were analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*weeks and baseline scores. Non-informative priors were considered.
Time frame: Baseline, Weeks 9-12
Participants took part in 19 investigative sites in 5 countries.
| Milestone | LOU064 | Placebo |
|---|---|---|
| Started | 47 | 29 |
| Pk analysis set | 33 | 0 |
| Pd analysis set | 47 | 29 |
| Completed | 35 | 19 |
| Not completed | 12 | 10 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Study terminated by sponsor | 12 | 7 |
| Withdrew: Subject decision | 0 | 1 |
FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre-dose. The baseline pre-dose FEV1 is defined as the average of the FEV1 measurements performed 45 min and 15 min prior to dosing on Day 1. A positive change from baseline in pre-dose FEV1 is considered a favorable outcome. Change from baseline in pre-dose FEV1 was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*visit interaction and baseline pre-dose FEV1. A weakly informative prior was considered for the placebo response.
| liters | LOU064 | Placebo |
|---|---|---|
| Change From Baseline in Pre-dose FEV1 at Week 12 | 0.105 ± 0.0494 | 0.075 ± 0.0497 |
Pharmacokinetic (PK) parameters were calculated based on LOU064 blood concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1 ng/mL. Cmax was determined using non-compartmental methods.
| ng/mL | LOU064 | Placebo |
|---|---|---|
| Day 15 | 239 ± 152 | — |
| Day 85 | 222 ± 142 | — |
PK parameters were calculated based on LOU064 blood concentrations determined by a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. Tmax was determined using non-compartmental methods.
| hours (hr) | LOU064 | Placebo |
|---|---|---|
| Day 15 | 1.00 (0.483 to 2.00) | — |
| Day 85 | 1.00 (0.500 to 3.00) | — |
PK parameters were calculated based on LOU064 blood concentrations determined by a validated LC-MS/MS method with a lower limit of quantification of 1 ng/mL. AUC0-24h was determined using non-compartmental methods. The linear trapezoidal rule was used for AUC0-24h calculation.
| hr*ng/mL | LOU064 | Placebo |
|---|---|---|
| Day 15 | 471 ± 285 | — |
| Day 85 | 517 ± 342 | — |
The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the overall ACQ-5 score is the mean of all 5 questions, therefore between 0 (totally controlled) and 6 (severely uncontrolled). The baseline values of ACQ-5 were collected at the baseline visit. A negative change from baseline in ACQ-5 is considered a favorable outcome. Change from baseline in ACQ-5 score was analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*visit interaction and baseline ACQ-5 score. Non-informative priors were considered.
| score on scale | LOU064 | Placebo |
|---|---|---|
| Change From Baseline in Asthma Symptom Questionnaire-5 Score (ACQ-5) at Week 12 | -0.95 ± 0.133 | -0.86 ± 0.164 |
PEF (Peak Expiratory Flow) is a person's maximum speed of expiration. All participants were instructed to record PEF twice daily before taking any medication using an electronic peak expiratory flow device (ePEF), once in the morning and once approximately 12 h later in the evening at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. For each day the best value in the morning and in the evening were considered and mean values on 4-week intervals were derived. The baseline values of PEF were the mean values in the run-in period. A positive change from baseline in PEF is considered a favorable outcome. Change from baseline in mean morning and mean evening PEF were analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*weeks interaction and baseline PEF values. Non-informative priors were considered.
| liters/minute | LOU064 | Placebo |
|---|---|---|
| Change from baseline in mean morning PEF | -2.4 ± 4.30 | -2.6 ± 5.59 |
| Change from baseline in mean evening PEF | -9.7 ± 5.58 | -6.3 ± 7.23 |
Participants were given a short acting β2-agonist (SABA; salbutamol, known also as albuterol) to use as rescue medication throughout the study along with an electronic diary (eDiary) to record rescue medication use. Participants recorded in the eDiary, once in the morning and once in the evening, the use of rescue medication (number of puffs of SABA taken in the previous 12 hours). The total number of puffs of SABA taken per day was calculated and the mean daily use of puffs of SABA over 12 weeks was derived. The baseline values of number of puffs of SABA taken per day were defined as the average from all non-missing records taken during the run-in period. A negative change from baseline is considered a favorable outcome. Change from baseline in number of puffs of SABA taken per day was analyzed using a Bayesian model, adjusting for effects of baseline SABA use, baseline FEV1, baseline asthma daytime symptom score and treatment. Non-informative priors were considered.
| puffs of SABA | LOU064 | Placebo |
|---|---|---|
| Change From Baseline in Number of Puffs of SABA Taken Per Day During the Treatment Period | -0.192 ± 0.0946 | -0.059 ± 0.1224 |
Participants recorded asthma symptoms twice daily in the eDiary. Daytime asthma symptoms were assessed before bed and nighttime symptoms on awakening. * Daytime asthma symptom score included 4 questions. Overall score (0 to 6) was calculated as the average of the 4 questions with higher values indicating more asthma symptoms. * Nighttime asthma symptom score included 2 questions. Overall score (0 to 3.5) was calculated as the average of the 2 questions with higher values indicating more asthma symptoms. Mean values of both scores were calculated over 4-week intervals during the treatment period. The baseline values of both asthma symptoms scores were defined as the average score during the run-in period. A negative change from baseline is a favorable outcome. Change from baseline in daytime and nighttime asthma symptom score were analyzed using a Bayesian model for repeated measures, adjusting for effects of treatment\*weeks and baseline scores. Non-informative priors were considered.
| score on scale | LOU064 | Placebo |
|---|---|---|
| Change from baseline in daytime asthma symptom score | -0.225 ± 0.0962 | -0.175 ± 0.1237 |
| Change from baseline in nighttime asthma symptom score | -0.120 ± 0.0488 | -0.195 ± 0.0651 |
Collected over From first dose of study treatment until last dose of study treatment plus 30 days post treatment, up to Day 115.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LOU064 | 0/47 (0%) | 0/47 (0%) | 8/47 (17%) |
| Placebo | 0/29 (0%) | 0/29 (0%) | 10/29 (34.5%) |
| Event | LOU064 | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 4/47 | 6/29 |
| Upper respiratory tract infectionInfections and infestations | 4/47 | 4/29 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/47 | 2/29 |
| Age, Continuous(years) | LOU064 | Placebo | Total |
|---|---|---|---|
| Mean | 49.2 ± 10.96 | 53.2 ± 10.40 | 50.7 ± 10.85 |
| Sex: Female, Male(Participants) | LOU064 | Placebo | Total |
|---|---|---|---|
| Female | 28 | 22 | 50 |
| Male | 19 | 7 | 26 |
| Race/Ethnicity, Customized(Participants) | LOU064 | Placebo | Total |
|---|---|---|---|
| Caucasian | 42 | 27 | 69 |
| Black | 4 | 2 | 6 |
| Asian | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Jul 2019 to primary completion in Apr 2020, 9 months.
Results were first posted in Apr 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remibrutinib